'A precedent you might not want to set.' FDA-invited expert blasts Moderna unblinding plan as adcomm gets underway
At last week’s advisory committee, Pfizer executives shot down a proposal from a Stanford expert on how to keep a blinded study going even after the vaccine becomes available. On Thursday, the FDA brought the same expert back, who again argued for the blinded plan and gave an even more forceful — albeit polite — denunciation of Moderna’s plan.
“This is a precedent you might not want to set,” Steven Goodman, associate dean of clinical and translational research at the Stanford University School of Medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.